571 results match your criteria Prostate Cancer - Neoadjuvant Androgen Deprivation


Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.

Clin Transl Radiat Oncol 2019 Jan 17;14:51-58. Epub 2018 Nov 17.

Department of Urology, Nara Medical University, Japan.

Purpose: To investigate chronological changes in lower urinary tract symptoms (LUTS) in patients who received iodine-125 brachytherapy (BT) for prostate cancer.

Methods: We enrolled 706 patients who received BT. Of these, 265 (38%) received BT combined with external beam radiation therapy (EBRT). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24056308183005
Publisher Site
http://dx.doi.org/10.1016/j.ctro.2018.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282112PMC
January 2019
12 Reads

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer.

Strahlenther Onkol 2018 Nov 26. Epub 2018 Nov 26.

Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Purpose: Accurate prostate cancer (PCa) detection is essential for planning focal external beam radiotherapy (EBRT). While biparametric MRI (bpMRI) including T2-weighted (T2w) and diffusion-weighted images (DWI) is an accurate tool to localize PCa, its value is less clear in the case of additional androgen deprivation therapy (ADT). The aim of this study was to investigate the value of a textural feature (TF) approach on bpMRI analysis in prostate cancer patients with and without neoadjuvant ADT with respect to future dose-painting applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-018-1402-3DOI Listing
November 2018
2 Reads

Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study.

Jpn J Clin Oncol 2019 Jan;49(1):87-91

Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy174DOI Listing
January 2019
10 Reads

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.

Ann Surg Oncol 2019 Jan 14;26(1):297-305. Epub 2018 Nov 14.

Dana-Farber/Brigham and Women's Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Purpose: In this study, we sought to describe the contemporary trends in utilization of neoadjuvant androgen deprivation therapy (ADT). As a secondary endpoint, we assessed the community-level effect of neoadjuvant ADT on positive surgical margins after radical prostatectomy (RP).

Methods: Using the National Cancer Database (2004-2014), we identified patients with clinically localized prostate cancer (PCa) [cT1-4N0M0] treated with RP. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-018-7035-z
Publisher Site
http://dx.doi.org/10.1245/s10434-018-7035-zDOI Listing
January 2019
14 Reads

Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.

Int J Clin Pract 2018 Nov 10:e13292. Epub 2018 Nov 10.

Division of Cancer and Genetics, School of Medicine, Cardiff University and Velindre Cancer Centre, Cardiff, UK.

Aim: To explore the practice and attitudes of uro-oncologists in the UK regarding monitoring testosterone levels and the use of testosterone replacement therapy (TRT) in their prostate cancer patients treated with androgen deprivation therapy (ADT).

Methods: An expert-devised online questionnaire was completed by the members of the British Uro-oncology Group (BUG).

Results: Of 160 uro-oncologists invited, 84 completed the questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijcp.13292DOI Listing
November 2018
6 Reads

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.

Eur Urol 2018 Nov 5. Epub 2018 Nov 5.

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting.

Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183083
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.10.042DOI Listing
November 2018
6 Reads

The addition of chemotherapy in the definitive management of high risk prostate cancer.

Urol Oncol 2018 11 9;36(11):475-487. Epub 2018 Oct 9.

Department of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, GA; Winship Cancer Institute at Emory University, Atlanta, GA.

In attempt to improve long-term disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX)-either adjuvant or neoadjuvant-to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT). Neoadjuvant trials generally confirm safety, feasibility, and pre-RP PSA reduction, but rates of pathologic complete response are rare, and no indications for neoadjuvant CTX have been firmly established. Adjuvant regimens have included CTX alone or in combination with androgen deprivation therapy (ADT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214780PMC
November 2018
2 Reads

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.

Eur Urol 2019 01 2;75(1):44-60. Epub 2018 Oct 2.

Institut Gustave Roussy, University of Paris Sud, Villejuif, France.

Context: Systemic therapies, combined with local treatment for high-risk prostate cancer, are recommended by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field.

Objective: To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer.

Evidence Acquisition: We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183054
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.07.027DOI Listing
January 2019
5 Reads

Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression.

BJU Int 2018 Sep 24. Epub 2018 Sep 24.

Departments of Urology and Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria,, Australia.

Objective: To characterise the pattern of late biochemical recurrence (BCR) in the largest contemporary cohort of patients with localised prostate cancer treated with radical prostatectomy (RP) in the active surveillance era.

Patients And Methods: Consecutive patients who underwent RP for localised prostate cancer between 2003 and 2017 were identified from a prospectively recorded, dedicated prostate cancer database. Patients who received neoadjuvant androgen-deprivation therapy were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14556DOI Listing
September 2018

Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study.

Minerva Urol Nefrol 2018 Sep 19. Epub 2018 Sep 19.

Department of Urology, ASL Abruzzo2, Chieti, Italy.

Background: Androgen-deprivation therapy is one of the options available for treating both advanced and metastatic prostate cancer (PCa). It is used as an adjuvant or neoadjuvant therapy, either alone or in combination with radiotherapy (RT) or surgery. The aim of this study is to appraise adherence to ADT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0393-2249.18.03109-0DOI Listing
September 2018
4 Reads

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Prostate Cancer Prostatic Dis 2019 03 31;22(1):117-124. Epub 2018 Aug 31.

University of California, San Francisco CA, USA.

Background: Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT.

Methods: The CaPSURE database contains 14,863 men with prostate cancer, including 1337 men diagnosed between 1990 and 2014 with localized disease who received EBRT as primary treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0084-3DOI Listing
March 2019
1 Read

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.

Prostate Int 2018 Sep 21;6(3):104-109. Epub 2017 Nov 21.

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background: We aimed to identify the candidate prostate cancer patients suitable for neoadjuvant androgen-deprivation therapy (ADT) with radical prostatectomy (RP).

Materials And Methods: This study included 711 Japanese patients with clinically localized prostate cancer who were treated with RP between 2000 and 2013. Patients were treated with or without neoadjuvant ADT before RP. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22878882173011
Publisher Site
http://dx.doi.org/10.1016/j.prnil.2017.10.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104286PMC
September 2018
14 Reads

Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy.

Onco Targets Ther 2018 3;11:4551-4558. Epub 2018 Aug 3.

Thyroid and Parathyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China,

Background: This study investigated the prognostic value of inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy with or without neoadjuvant androgen deprivation therapy (ADT).

Methods: Inflammation-based scores included the neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and plasma fibrinogen. A total of 440 patients (380 patients treated without neoadjuvant ADT and 60 patients treated with neoadjuvant ADT) were retrospectively evaluated in our medical center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S151314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082347PMC
August 2018
6 Reads

Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test.

Prostate Cancer Prostatic Dis 2018 11 7;21(4):594-603. Epub 2018 Aug 7.

Department of Pathology, Icahn School of Medicine at Mt. Sinai, 1468 Madison Avenue, New York City, NY, 10029, USA.

Background: Postoperative risk assessment remains an important variable in the effective treatment of prostate cancer. There is an unmet clinical need for a test with the potential to enhance the Gleason grading system with novel features that more accurately reflect a personalized prediction of clinical failure.

Methods: A prospectively designed retrospective study utilizing 892 patients, post radical prostatectomy, followed for a median of 8 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0067-4DOI Listing
November 2018
17 Reads

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Int J Radiat Oncol Biol Phys 2018 Jul 5;101(4):883-888. Epub 2018 Apr 5.

Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California. Electronic address:

Purpose: Gleason score (GS) 10 disease is the most aggressive form of clinically localized prostate adenocarcinoma (PCa). The long-term clinical outcomes and overall prognosis of patients presenting with GS 10 PCa are largely unknown because of its rarity.

Methods And Materials: The study included 112 patients with biopsy-determined GS 10 PCa who received treatment with radical prostatectomy (RP, n = 26), external beam radiation therapy (EBRT, n = 48), or EBRT with a brachytherapy boost (EBRT-BT, n = 38) between 2000 and 2013. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016183061
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2018.03.060DOI Listing
July 2018
9 Reads

Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.

Andrology 2018 Nov 2;6(6):903-908. Epub 2018 Jul 2.

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Although reports have shown evidence for penile length (PL) shortening after radical prostatectomy (RP), the association between neoadjuvant androgen deprivation therapy (NADT) and PL after RP has yet to be determined. This study evaluates chronological changes in PL after NADT and RP. Stretched PLs (SPLs) of 143 patients, 41 of whom had undergone NADT, were measured before, 10 days after, and 1, 3, 6, 9, 12, 18, and 24 months after RP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/andr.12517DOI Listing
November 2018
5 Reads

Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.

BJU Int 2019 Feb 27;123(2):277-283. Epub 2018 Aug 27.

Department of Urology, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Objectives: To report the long-term results of prostate brachytherapy followed by external beam radiotherapy (EBRT) in men with a positive seminal vesicle biopsy (+SVB).

Patients And Methods: In all, 1081 men with localised prostate cancer were treated with permanent brachytherapy, of which 615 had staging SVB and 53 (9.4%) were positive. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.14464
Publisher Site
http://dx.doi.org/10.1111/bju.14464DOI Listing
February 2019
6 Reads

Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.

Brachytherapy 2018 Sep - Oct;17(5):799-807. Epub 2018 Jun 21.

Department of Radiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Purpose: We analyzed factors associated with rectal toxicity after iodine-125 prostate brachytherapy (BT) with or without external beam radiation therapy (EBRT).

Methods And Materials: In total, 2216 prostate cancer patients underwent iodine-125 BT with or without EBRT between 2003 and 2013. The median followup was 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.05.008DOI Listing
June 2018
10 Reads

[Morphological changes in tumor and nontumor tissue in the treatment of prostate adenocarcinoma with high-intensity focused ultrasound in combination with androgen deprivation].

Arkh Patol 2018 ;80(3):26-33

Altai State Medical University, Ministry of Health of the Russia, Barnaul, Russia.

Objective: To investigate structural changes in the tumor and nontumor tissues of the prostate in patients with its cancer (PC) after treatment with high-intensity focused ultrasound (HIFU) in combination with androgen deprivation to clarify criteria for evaluating the efficiency of treatment.

Subject And Methods: Comparative morphological, immunohistochemical, and morphometric analyses were carried out to examine 253 pre- and postoperative biopsy specimens, as well as transurethral resection specimens from 32 patients with localized PC and with or without a local recurrence within 3 years after a HIFU session.

Results: HIFU ablation was accompanied by coagulation necrosis and progressive pancreatic fibrosis with complete tumor regression or by a reduction in the number of positive columns (by an average of 58%) in cases with recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/patol201880326-33DOI Listing
January 2018
2 Reads

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Cancer Res 2018 Aug 19;78(16):4716-4730. Epub 2018 Jun 19.

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Primary prostate cancer can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. In this study, we microdissected residual prostate cancer foci in radical prostatectomies from 18 men treated with neoadjuvant-intensive androgen deprivation therapy (leuprolide, abiraterone acetate, and prednisone) and analyzed them for resistance mechanisms. Transcriptome profiling showed reduced but persistent androgen receptor (AR) activity in residual tumors, with no increase in neuroendocrine differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095796PMC
August 2018
18 Reads

Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.

Urol Oncol 2018 08 7;36(8):364.e9-364.e14. Epub 2018 Jun 7.

Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA.

Background: Recent studies suggest that anesthetic technique during radical prostatectomy for prostate cancer may affect recurrence or progression. This association has previously been investigated in series that employ epidural analgesia. The objective of this study is to determine the association between the use of a multimodal analgesic approach incorporating paravertebral blocks and risk of biochemical recurrence following open radical prostatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.05.016DOI Listing
August 2018
14 Reads

Systemic treatments for high-risk localized prostate cancer.

Nat Rev Urol 2018 Aug;15(8):498-510

Department of Oncology, Antoine-Lacassagne Center, Nice, France.

The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41585-018-0017-x
Publisher Site
http://dx.doi.org/10.1038/s41585-018-0017-xDOI Listing
August 2018
18 Reads

The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An F-MISO PET-MRI Study.

Int J Radiat Oncol Biol Phys 2018 Nov 8;102(4):1210-1218. Epub 2018 Mar 8.

Radiation Oncology, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, Geneva University, Geneva, Switzerland.

Purpose: Tumor hypoxia is associated with radioresistance and poor prognosis after radiation therapy for prostate cancer (PCa). In this prospective pilot study, we assessed the ability of F-misonidazole (F-MISO) positron emission tomography (PET)-magnetic resonance imaging (MRI) to detect hypoxia in high-grade PCa patients who were candidates for curative radiation therapy, and we evaluated F-MISO PET-MRI modulation after 3 months of neoadjuvant androgen deprivation therapy (nADT).

Methods And Materials: Eleven PCa patients with a Gleason score (GS) ≥ 8 underwent F-fluorocholine (F-FCH) PET-computed tomography at diagnosis and an F-MISO hybrid PET-MRI examination before nADT; a second F-MISO PET-MRI examination was acquired after 3 months of nADT for all patients but one who dropped out because of noncompliance with nADT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.02.170DOI Listing
November 2018
7 Reads

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

BMC Cancer 2018 04 2;18(1):354. Epub 2018 Apr 2.

Urology, Department of Development and Regeneration, University Hospitals Leuven, Leuven, Belgium.

Background: Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for early stage disease. Apalutamide is a pure androgen antagonist with a very high affinity with the androgen receptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4275-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879743PMC
April 2018
18 Reads

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.

Clin Oncol (R Coll Radiol) 2018 Jun 17;30(6):334-345. Epub 2018 Feb 17.

School of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Aims: To identify symptom clusters and predisposing factors associated with long-term symptoms and health-related quality of life after radiotherapy in men with prostate cancer.

Materials And Methods: Patient-reported outcomes (PROs) data from the Medical Research Council RT01 radiotherapy with neoadjuvant androgen deprivation therapy trial of 843 patients were used. PROs were collected over 5 years with the University of California, Los Angeles Prostate Cancer Index (UCLA-PCI) and the 36 item Short-Form Health Survey (SF-36). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09366555183004
Publisher Site
http://dx.doi.org/10.1016/j.clon.2018.01.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952898PMC
June 2018
1 Read

Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group.

Cancer Med 2018 Mar 14;7(3):677-689. Epub 2018 Feb 14.

Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

This is the first multi-institutional retrospective survey of the long-term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852348PMC
March 2018
12 Reads

Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.

Minerva Urol Nefrol 2018 Aug 1;70(4):370-379. Epub 2018 Feb 1.

Unit of Medical Oncology, ASST Spedali Civili, University of Brescia, Brescia, Italy.

Introduction: Androgen-deprivation therapy (ADT) administered in neoadjuvant setting before radical prostatectomy (RP) represents an ideal in vivo human model to test the efficacy of hormonal treatments in prostate cancer (PCa). This review summarizes the findings from published studies specifically focused on the biological effects of ADT assessed on specimens from RP. The aim is to provide a base of knowledge that might be used to design future studies on neoadjuvant therapy for PCa. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R19Y2018N04A037
Publisher Site
http://dx.doi.org/10.23736/S0393-2249.18.03022-9DOI Listing
August 2018
9 Reads

Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study.

Mol Clin Oncol 2018 Jan 3;8(1):141-146. Epub 2017 Nov 3.

Department of Oncology-Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden.

To avoid pubic arch interference, prostate cancer patients are treated with neoadjuvant androgen deprivation therapy (ADT) to achieve prostate volume (PV) reduction prior to radiation treatment. The aim of the present randomised study was to compare the effects on PV of two regimens of ADT, an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2017.1487DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769271PMC
January 2018
3 Reads

Neoadjuvant and adjuvant treatment in high-risk prostate cancer.

Expert Rev Clin Pharmacol 2018 Apr 25;11(4):425-438. Epub 2018 Jan 25.

a Division of Oncology/Unit of Urology , URI, IRCCS Hospital San Raffaele , Milan , Italy.

Introduction: High-risk prostate cancer (HRPCa) represents a heterogeneous disease with potential risk for local and distant progression. In these patients, a multi-modal approach consisting of neoadjuvant and/or adjuvant systemic therapies has been proposed. The aim of this review is to summarize the emerging roles of neoadjuvant and adjuvant therapies in HRPCa patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1429265DOI Listing
April 2018
9 Reads

Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.

Int J Urol 2018 04 11;25(4):352-358. Epub 2018 Jan 11.

Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.

Objectives: To determine the predictors of testosterone recovery after termination of androgen deprivation therapy in high/intermediate-risk prostate cancer patients receiving external beam radiation therapy with neoadjuvant and adjuvant androgen deprivation therapy.

Methods: A total of 82 patients who underwent external beam radiation therapy with androgen deprivation therapy for prostate cancer were retrospectively analyzed. Serum testosterone levels after androgen deprivation therapy terminations were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13521DOI Listing
April 2018
21 Reads

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.

Eur Urol 2018 06 4;73(6):968-976. Epub 2018 Jan 4.

Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK. Electronic address:

Background: The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain.

Objective: To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation.

Design, Setting, And Participants: Between 1998 and 2001, 843 men with localised prostate cancer were randomised to receive either control-64Gy or escalated-74Gy conformal radiotherapy (CFRT) in the MRC RT01 trial in combination with 3-6-mo neoadjuvant androgen deprivation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.12.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954168PMC
June 2018
5 Reads

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

Prostate Cancer Prostatic Dis 2018 09 20;21(3):364-372. Epub 2017 Dec 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease.

Methods: In this analysis, we report on the post-RP outcomes of a subset of patients enrolled on these studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-017-0009-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013399PMC
September 2018
18 Reads

Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.

Int J Radiat Oncol Biol Phys 2018 01 13;100(1):59-67. Epub 2017 Oct 13.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

Purpose: To evaluate the difference in prostate-specific antigen (PSA) recurrence-free, distant metastasis-free, overall, and cancer-specific survival between PSA bounce (PSA-B) and non-bounce patients treated with dose-escalated external beam radiation therapy (DE-EBRT).

Methods And Materials: During 1990-2010, 1898 prostate adenocarcinoma patients were treated with DE-EBRT to ≥75 Gy with ≥5 years follow-up. Patients receiving neoadjuvant/concurrent androgen-deprivation therapy (n=1035) or with fewer than 4 PSA values obtained 6 months or more after post-EBRT completion (n=87) were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2017.09.003DOI Listing
January 2018
19 Reads
4.258 Impact Factor

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.

BMC Cancer 2017 Nov 23;17(1):789. Epub 2017 Nov 23.

Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.

Background: The magnitude and rapidity of the tumor response to androgen deprivation is known to predict the durability of the therapy. We have investigated the predictive value of categorizing patients by the half-life of PSA under neoadjuvant androgen deprivation therapy in patients with biochemical recurrence after radical prostatectomy.

Methods: Medical records of 317 patients who received neoadjuvant androgen deprivation therapy before radical prostatectomy and developed biochemical recurrence were analyzed. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-017-3775-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701379PMC
November 2017
12 Reads

Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.

Clin Genitourin Cancer 2018 04 23;16(2):135-141.e1. Epub 2017 Sep 23.

Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Introduction: External beam radiation therapy (EBRT) with short-term androgen deprivation therapy is the standard of care for intermediate-risk prostate cancer patients. However, no study to date has evaluated the hormonal kinetics or sexual and hormonal function recovery after cessation of short-term luteinizing hormone (LH)-releasing hormone (LHRH) antagonist treatment.

Patients And Methods: Ten intermediate-risk prostate cancer patients (mean age, 69. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.09.009DOI Listing
April 2018
23 Reads

[Radiation therapy of locally advanced prostate cancer].

Urologe A 2017 Nov;56(11):1402-1409

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der Universität München - LMU, Marchioninistr. 15, 81377, München, Deutschland.

The risk classification for localized prostate cancer is based on the groups "low", "intermediate", and "high-risk" prostate cancer. Following this established risk group definition, locally advanced prostate cancer (cT3/4N0M0) has to be classified as "high-risk" prostate cancer. Radical prostatectomy or high-dose radiotherapy, which is combined with androgen deprivation, are the only curative standard treatments for locally advanced prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-017-0511-4DOI Listing
November 2017
6 Reads

Pathological and oncological features of Korean prostate cancer patients eligible for active surveillance: analysis from the K-CaP registry.

Jpn J Clin Oncol 2017 Oct;47(10):981-985

Department of Urology, Yonsei University College of Medicine.

Background: A web-based multicenter Korean Prostate Cancer Database (K-CaP) was established to provide urologists with information on Korean prostate cancer (PCa) patients treated with radical prostatectomy (RP). We utilized the K-CaP registry to identify pathological features and oncological outcomes of Korean PCa patients eligible for active surveillance (AS).

Methods: The K-CaP registry consisted of 6415 patients who underwent RP from May 2001 to April 2013 at five institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyx101DOI Listing
October 2017
16 Reads

Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.

Prostate 2017 Nov 14;77(15):1520-1527. Epub 2017 Sep 14.

Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan.

Background: We evaluated a five-tiered Gleason grade groups arising from the 2014 International Society of Urological Pathology consensus conference on prognostic prediction in clinical stage T3a (extracapsular invasion) and T3b (seminal vesicle involvement) prostate cancer undergoing high-dose-rate brachytherapy (HDR-BT).

Methods: From November 2003 to December 2012, 283 patients with stage T3 prostate cancer received HDR-BT and external beam radiation therapy (EBRT) with long-term androgen deprivation therapy (ADT). Of these, 203 (72%) and 80 (28%) patients had stage T3a and T3b disease, respectively. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.23430
Publisher Site
http://dx.doi.org/10.1002/pros.23430DOI Listing
November 2017
10 Reads

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.

Clin Cancer Res 2017 Nov 11;23(22):6812-6822. Epub 2017 Sep 11.

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) blockade has been unsuccessful in prostate cancer, with poor immunogenicity and subsequent low PD-L1 expression in prostate cancer being proposed as an explanation. However, recent studies indicate that a subset of prostate cancer may express significant levels of PD-L1. Furthermore, the androgen antagonist enzalutamide has been shown to upregulate PD-L1 expression in prostate cancer preclinical models. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-0807DOI Listing
November 2017
9 Reads

Long-term outcomes in patients treated with proton therapy for localized prostate cancer.

Cancer Med 2017 Oct 6;6(10):2234-2243. Epub 2017 Sep 6.

Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.

The aim of this retrospective study was to report long-term clinical outcomes in patients treated with proton therapy (PT) for localized prostate cancer. Between 2001 and 2014, 1375 consecutive patients were treated with PT. Patients were classified into prognostic risk groups based on the National Comprehensive Cancer Network criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633560PMC
October 2017
34 Reads

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Clin Cancer Res 2017 Nov 25;23(22):6802-6811. Epub 2017 Aug 25.

Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approach earlier in the disease. Specimens from this trial offer a unique opportunity to interrogate the acute molecular response to docetaxel and ADT and identify potential biomarkers. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690882PMC
November 2017
20 Reads

Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.

Aging Male 2018 Mar 22;21(1):17-23. Epub 2017 Aug 22.

f Department of Urology, Eulji General Hospital, Eulji University School of Medicine , Seoul , Republic of Korea.

Objective: To determine whether radical prostatetomy (RP) is suitable for prostate cancer patients with age ≥75 years in comparison to primary androgen deprivation therapy (PADT).

Patients And Methods: A cohort study was conducted in clinically localized prostate cancer patients with ≥75 years of age who underwent RP or PADT at six institutions from 2005 to 2013. Patients who had less than 12 months of follow-up, or received neoadjuvant or adjuvant therapy were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13685538.2017.1365122DOI Listing
March 2018
15 Reads

Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer.

Urol Oncol 2017 11 7;35(11):663.e15-663.e21. Epub 2017 Aug 7.

Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Birmingham, AL.

Purpose/objective(s): To assess subcutaneous adipose tissue characteristics by computed tomography (CT) as potential imaging biomarkers predictive of biochemical recurrence in men with high-risk prostate cancer receiving radiotherapy (RT).

Materials And Methods: This retrospective study included men with high-risk prostate cancer (PSA>20ng/ml, Gleason score ≥8, or clinical extraprostatic extension) treated between 2001 and 2012. All patients received definitive, dose-escalated external beam RT along with a course of neoadjuvant, concurrent, and adjuvant androgen deprivation therapy (ADT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.07.012DOI Listing
November 2017
20 Reads

Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.

Adv Radiat Oncol 2016 Oct-Dec;1(4):317-324. Epub 2016 Aug 18.

Division of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania.

Purpose: A phase 2 protocol was designed and implemented to assess the toxicity and efficacy of hypofractionated image guided intensity modulated radiation therapy (IG-IMRT) combined with low-dose rate Pd prostate seed implant for treatment of localized intermediate- and high-risk adenocarcinoma of the prostate.

Methods And Materials: This is a report of an interim analysis on 24 patients enrolled on an institutional review board-approved phase 2 single-institution study of patients with intermediate- and high-risk adenocarcinoma of the prostate. The median pretreatment prostate-specific antigen level was 8. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24521094163005
Publisher Site
http://dx.doi.org/10.1016/j.adro.2016.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514232PMC
August 2016
8 Reads

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Endocr Relat Cancer 2017 08 29;24(8):393-404. Epub 2017 Jun 29.

Department of Systems Pharmacology & Translational TherapeuticsPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Neoadjuvant androgen deprivation therapy (NADT) is one strategy for the treatment of early-stage prostate cancer; however, the long-term outcomes of NADT with radical prostatectomy including biochemical failure-free survival are not promising. One proposed mechanism is incomplete androgen ablation. In this study, we aimed to evaluate the efficiency of serum hydroxy-androgen suppression in patients with localized high-risk prostate cancer under NADT (leuprolide acetate plus abiraterone acetate and prednisone) and interrogate the primary sources of circulating hydroxy-androgens using our recently described stable isotope dilution liquid chromatography mass spectrometric method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-17-0107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593253PMC
August 2017
24 Reads

Radical Prostatectomy for Locally Advanced Prostate Cancers-Review of Literature.

Indian J Surg Oncol 2017 Jun 5;8(2):175-180. Epub 2017 Jan 5.

Department of Uro-Oncology, HCG Bangalore Institute of Oncology, Bangalore, India.

Twenty-five to thirty percent of patients with prostate cancer present with locally advanced disease. While risk stratification remains the same with high incidence of upstaging of disease on imaging and histopathological evaluation; there have been progressive refinements in surgical therapy. With availability of reasonably robust data, radical prostatectomy in men with locally advanced prostate cancers seems to effect improvement in both cancer specific and overall survival rates in comparison to the current standard of care of radiation with androgen deprivation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13193-016-0599-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427032PMC
June 2017
18 Reads

External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer.

J Sex Med 2017 07 22;14(7):876-882. Epub 2017 May 22.

Department of Radiation Oncology, University of Montreal Health Center, Montreal, Canada.

Background: Previous studies have examined testosterone levels after external beam radiation (EBRT) monotherapy, but since 2002 only sparse contemporary data have been reported.

Aim: To examine testosterone kinetics in a large series of contemporary patients after EBRT.

Methods: The study was conducted in 425 patients who underwent definitive EBRT for localized prostate cancer from 2002 through 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsxm.2017.04.675DOI Listing
July 2017
38 Reads

I brachytherapy in younger prostate cancer patients : Outcomes in low- and intermediate-risk disease.

Strahlenther Onkol 2017 Sep 9;193(9):707-713. Epub 2017 May 9.

Department of Radiation Oncology, AZ Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium.

Purpose: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) I brachytherapy (BT) for localized prostate cancer.

Patients And Methods: A total of 192 patients (≤65-years-old) were treated with LDR I-BT ± hormone therapy. Local failure was defined as any prostate-specific antigen (PSA) rise leading to salvage treatment or biochemical failure according to the Phoenix definition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-017-1142-9DOI Listing
September 2017
13 Reads

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

Int J Radiat Oncol Biol Phys 2017 06 22;98(2):304-317. Epub 2017 Feb 22.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

Purpose: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer.

Methods And Materials: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2017.02.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493021PMC
June 2017
27 Reads